Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Sodium nitroprusside is a potent and fast-acting intravenous vasodilator used primarily for the immediate reduction of blood pressure in hypertensive emergencies and acute heart failure. It is also employed to reduce bleeding during surgery by inducing controlled hypotension. Sodium nitroprusside acts as a prodrug that releases nitric oxide (NO) upon metabolism in the bloodstream. The released NO activates guanylate cyclase in vascular smooth muscle cells, increasing cyclic GMP levels and leading to relaxation of both arterioles and venules (with slightly greater effect on veins). This results in rapid peripheral vasodilation and decreased vascular resistance[1][2][3][4][5][6][8].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on sodium nitroprusside.